治疗慢性肝病的新药:辛伐他汀*

doi:10.3969/j.issn.1672-5069.2021.04.038

Abstract

Abstract: Objective Besides its lipid-lowering function, the simvastatin also exhibits multiple pleiotropic effects, such as antioxidative, antiproliferative and antiinflammatory properties, as well as the capacity to improve endothelial function and to stimulate neoangiogenesis. It rarely lead to apparent clinical acute liver injury, and might be a new choice for the treatment of patients with chronic liver diseases. In this article, we briefly introduce the basic and clinical researches of simvastatin in the treatment of patients with chronic liver diseases.

Key words: Chronic liver diseases, Simvastatin, Therapy

Bi Zaihong, Hanbai Yila, Wang Bingyuan. Simvastatin: a newface for treatment of patients with chronic liver disease[J]. Journal of Practical Hepatology, 2021, 24(4): 603-606.

References

[1] Pose E, Trebicka J, Mookerjee RP, et al. Statins: Old drugs as new therapy for liver diseases? J Hepatol,2019,70(1):194-202.
[2] Wen J, Wu Y, Wei W, et al. Protective effects of recombinant human cytoglobin against chronic alcohol-induced liver disease in vivo and in vitro.Sci Rep,2017,7:41647.
[3] Guixé-Muntet S, de Mesquita FC, Vila S, et al. Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. J Hepatol, 2017,66(1):86-94.
[4] Meireles CZ, Pasarin M, Lozano JJ, et al. Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage/resuscitation.Shock,2017,47(3):370-377.
[5] Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology,2004,126(3):749-755.
[6] Pollo-Flores P, Soldan M, Santos UC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. Dig Liver Dis,2015,47(11):957-963.
[7] Abraldes JG, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology, 2009,136(5):1651-1658.
[8] Bishnu S, Ahammed SM, Sarkar A, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension. Eur J Gastroenterol Hepatol, 2018,30(1):54-59.
[9] Jiang H. Simvastatin protects high glucose-induced H9c2 cells from injury by inducing autophagy. Pharm Biol,2020,58(1):1077-1084.
[10] Li H, Rabearivony A, Zhang W, et al. Chronopharmacology of simvastatin on hyperlipidaemia in high-fat diet-fed obese mice. J Cell Mol Med,2020,24(18):11024-11029.
[11] Hide D, Warren A, Fernández-Iglesias A, et al. Ischemia/reperfusion injury in the aged liver: The importance of the sinusoidal endothelium in developing therapeutic strategies for the elderly. J Gerontol A Biol Sci Med Sci,2020,75(2):268-277.
[12] Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins.Gut,2020,69(5):953-962.
[13] Liu Z, Lai CH, Zhang X, et al. Simvastatin ameliorates total liver ischemia/reperfusion injury via KLF2-mediated mechanism in rats. Clin Res Hepatol Gastroenterol,2019,43(2):171-178.
[14] Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension.Gastroenterology,2018,155(5):1564-1577.
[15] La Mura V, Pasarín M, Meireles CZ, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction.Hepatology,2013,57(3):1172-1181.
[16] Baiges A, Hernández-Gea V, Bosch J. Pharmacologic prevention of variceal bleeding and rebleeding.Hepatol Int,2018,12(Suppl 1):68-80.
[17] Stolf AM, Lívero Fdos R, Dreifuss AA, et al. Effects of statins on liver cell function and inflammation in septic rats.J Surg Res, 2012,178(2):888-897.
[18] Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.Hepatology, 2017,66(3):896-907.
[19] Abraldes JG, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.Gastroenterology, 2009,136(5):1651-1658.
[20] Elwan N, Salah R, Hamisa M, et al. Evaluation of portal pressure by Doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial. F1000Res, 2018,7:256.
[21] Abraldes JG, Villanueva C, Aracil C, et al. BLEPS Study Group. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology, 2016,150(5):1160-1170.
[22] Feng J, Dai W, Mao Y, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.J Exp Clin Cancer Res, 2020,39(1):24.
[23] 张宁, 赵彩彦. 他汀类药物对肝细胞癌的作用与机制研究进展.实用肝脏病杂志,2015,18 (3): 329-332.
[24] Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals.J Hepatol,2015,63(3):705-712.
[25] Nascimbeni F, Aron-Wisnewsky J, Pais R, et al. LIDO study Group. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease.BMJ Open Gastroenterol,2016,3(1):e000075.
[26] 袁乐媛,韩惠芳,王炳元,等.酒精性肝病与血脂代谢相关性分析.胃肠病学和肝病学杂志,2015,24(8):973-976.
[27] 钟碧慧. 降脂药物在NAFLD患者中的合理应用. 实用肝脏病杂志, 2016,19(2):143-146.
[28] Atef MM, Hafez YM, Alshenawy HA, et al. Ameliorative effects of autophagy inducer, simvastatin on alcohol-induced liver disease in a rat model.J Cell Biochem,2018,234:136-143.
[29] Zhao G, Yu YM, Kaneki M, et al. Simvastatin protects hepatocytes from apoptosis by suppressing the TNF-α/caspase-3 signaling pathway in mice with burn injury.Ann Surg,2013,257(6):1129-1136.
[30] Carloni S, Balduini W. Simvastatin preconditioning confers neuroprotection against hypoxia-ischemia induced brain damage in neonatal rats via autophagy and silent information regulator 1 (SIRT1) activation.Exp Neurol,2020,324:113117.
[31] U.S. Food and Drug Administration (FDA). FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Rockville, MD, 2012. Available: http://www.fda.gov/drugs/drugsafety/ucm293101.htm.
[32] Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology,2004,126(5):1287-1292.
[33] Muñoz AE, Pollarsky F, Marino M, et al. Safety of chronic simvastatin treatment in patients with decompensated cirrhosis: Many adverse events but no liver injury. Dig Dis Sci,2020,84:2345-2349.
[34] Pose, E, Napoleone, L, Amin, A, et al. (2020). Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Gastroenterol Hepatol,2019,5(1), 31-41.
[35] Dickerman BA, García-Albéniz X, Logan RW, et al. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med, 2019,25(10):1601-1606.

Simvastatin: a newface for treatment of patients with chronic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[2]	Liu Yongchang, Zhao Diantang, Sun Qifeng, et al. Application of indocyanine green fluorescence navigationand three-dimensional visualization in laparoscopic precision surgery for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 561-564.
[3]	Gao Jinlong, Wang Haifeng, Li Na, et al. Target delineation accuracy of tumors for radiotherapy based on MR-T2 image in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(4): 565-568.
[4]	Wang Xuemei, Zhang Yao, Yang Xueping, et al. Clinical application of ultrasound-guided percutaneous aspiration and percutaneous catheter drainage for treatment of liver abscess patients with or without AIDS [J]. Journal of Practical Hepatology, 2021, 24(4): 573-576.
[5]	Tang Wentao, Huang Hui, Cai Chanjuan. Long-term curative effects of transarterial embolization with pingyangmycin-lipiodol suspension in the treatment of patients with hepatic hemangioma [J]. Journal of Practical Hepatology, 2021, 24(4): 581-584.
[6]	Fu Qianguang, Li Qian, Feng Xiaoxue, et al. Clinical efficacy of laparoscopic common bile duct exploration and laparoscopic cholecystectomy combination in the treatment of patients with cholecystolithiasis and choledocholithiasis [J]. Journal of Practical Hepatology, 2021, 24(4): 589-592.
[7]	An Xiquan, Li Yan, Menggen Caicike. Clinical observation of tenofovir and sorafenib in the treatment of patients with hepatitis B associated advanced primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 600-602.
[8]	Yuan Pingge, Chen Wenwen. Insights to new medicine development for treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 305-307.
[9]	Xu Wenting, Zhang Jihong, Wei Dongjue, et al. Efficacy of tenofovir rescue therapy for patients with chronic hepatitis B and rtM204 mutation [J]. Journal of Practical Hepatology, 2021, 24(3): 335-338.
[10]	Wang Xue, Qu Falin, Qi Weili, et al. Balance of peripheral blood Treg cells/ Th17 cells in patients with chronic hepatitis B and its impact on response to telbivudine treatment [J]. Journal of Practical Hepatology, 2021, 24(3): 339-342.
[11]	Qi Mei, Zhang Ruijin, Tian Shuping, et al. Impacting factors in response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 371-374.
[12]	Wang Yunqiang, Wang Liping, Huang Dongmei, et al. Changes ofportal hemodynamics in patients with hepatitis B cirrhosis after transjugular intrahepatic portosystemic stent-shunt [J]. Journal of Practical Hepatology, 2021, 24(3): 399-402.
[13]	Wu Chang, Zhang Yuan’an, Peng Chunfen. Efficacy of endoscopic variceal ligation and carvedilol maintenance in the treatment of patients with liver cirrhosis and esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2021, 24(3): 403-406.
[14]	Zhao Kai, Xue Jinfeng, Xue Pengfei, et al. Application of Viatorr covered stent in TIPS for treatment of cirrhotics with portal hypertension [J]. Journal of Practical Hepatology, 2021, 24(3): 419-422.
[15]	Feng Hao, Lyu Haitao, Wang Ziwei, et al. Efficacy of one-step and step-by-steplaparoscopic cholecystectomy in the treatment of patients with gallbladder stones and common bile duct stones [J]. Journal of Practical Hepatology, 2021, 24(3): 435-438.